Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Adicet Bio (Nasdaq: ACET) announced the formation of a Scientific Advisory Board (SAB) on July 15, 2021. This board comprises distinguished experts in T cell biology, immunology, and oncology, who will provide strategic guidance for advancing Adicet’s lead asset, ADI-001, and its gamma delta T cell therapies. Key members include renowned doctors such as Alice Bertaina, Marco Davila, and Michael Kalos. The new board is expected to enhance the development of innovative cancer treatments, boosting Adicet's potential in the biotechnology sector.
Adicet Bio, Inc. (Nasdaq: ACET) announced its addition to the Russell 2000 Index, effective June 28, 2021. This inclusion reflects the significant progress the company has made in developing allogeneic gamma delta T cell therapies for cancer treatment. CEO Chen Schor expressed optimism that this recognition will enhance visibility for its gamma delta T cell product pipeline. Adicet is expected to release interim clinical data from its lead candidate ADI-001 later this year. The Russell Indexes are utilized widely by institutional investors, managing approximately $10.6 trillion in assets.
Adicet Bio, a biotechnology firm focused on innovative gamma delta T cell therapies, announced participation in two virtual investor conferences. The first is the UBS Global Healthcare Virtual Conference from May 24-26, where CEO Chen Schor will present on May 26 at 7:00 AM ET. The second event is the JMP Securities Life Sciences Conference on June 16-17, featuring a fireside chat with Schor on June 16 at 3:00 PM ET. Live webcasts will be available on their website, with replays accessible for 30 days post-event.
Adicet Bio (Nasdaq: ACET) reported a productive Q1 2021, highlighted by the successful $143.8 million capital raise and the initiation of a Phase 1 trial for ADI-001, targeting B Cell Non-Hodgkin's Lymphoma (NHL). The trial is positioned as the first allogeneic CAR gamma-delta T cell therapy to enter human trials, with interim data expected by late 2021. Despite increased R&D and G&A expenses totaling $17.3 million, the company holds $223.4 million in cash and marketable securities, providing a strong financial foundation through mid-2023.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies for cancer, will have its CEO, Chen Schor, present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021, at 2:40 PM ET. A live audio webcast of the event will be available on their investors website, with an archived replay accessible for 30 days post-presentation. Adicet Bio is advancing engineered gamma delta T cells aimed at improving tumor targeting and immune response in patients.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm, has announced that its President and CEO, Chen Schor, will participate in a panel on Gamma Delta CART-Cells at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference on April 15, 2021. The panel, moderated by John Newman, Ph.D., will run from 1:00 PM to 1:55 PM ET. Adicet is focused on developing allogeneic gamma delta T cell therapies aimed at treating cancer and enhancing anti-tumor responses through innovative engineering techniques.
Adicet Bio, Inc. (Nasdaq: ACET) announced the appointment of Dr. Blake Aftab as Vice President of Research, effective April 13, 2021. Dr. Aftab will lead research efforts to advance the clinical development of ADI-001 and expand the pipeline of 'off-the-shelf' gamma delta T cell therapies. With nearly 20 years of experience in cell therapy development, Dr. Aftab aims to harness Adicet’s innovative platform for transformative patient treatments. His previous roles include significant contributions at Atara Biotherapeutics and academic research in multiple myeloma.
Adicet Bio, Inc. (Nasdaq: ACET) reported significant progress, including the IND clearance and initiation of its first-in-human Phase 1 trial for ADI-001, targeting B cell non-Hodgkin’s lymphoma. The company raised $143.6 million through a public offering to support its pipeline of CAR gamma-delta T cell therapies. For 2020, R&D expenses rose to $34.3 million, while G&A expenses hit $22.8 million. The net loss for the year was $36.7 million, or $5.01 per share, up from 2019's $28.1 million. Cash and marketable securities totaled $94.6 million at year-end, ensuring operational funding into 2023.
Adicet Bio (Nasdaq: ACET) has initiated its First-in-Human Phase I clinical trial for ADI-001, an innovative allogeneic gamma delta T cell therapy aimed at treating B cell non-Hodgkin's lymphoma (NHL). This open-label trial will enroll around 75 patients diagnosed with relapsed or refractory B cell malignancies. The primary focus is on evaluating ADI-001's safety, tolerability, and pharmacodynamics, with preliminary results expected by late 2021. The therapy's potential, based on encouraging preclinical data, suggests it could provide a new treatment option for NHL patients.
Adicet Bio, Inc. (Nasdaq: ACET) announced the appointment of Andrew Sinclair, Ph.D., to its board of directors, succeeding Erez Chimovits. Sinclair, a partner at Abingworth, brings significant life sciences investment experience, particularly related to biotechnology and pharmaceuticals. His addition follows a successful $152 million financing, highlighting investor confidence. The company aims to advance its gamma delta T cell therapies, with a focus on clinical development and expanding its product pipeline, addressing cancer and other diseases.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
What is Adicet Bio, Inc.?
What are the key products in Adicet Bio's pipeline?
What recent achievements has Adicet Bio made?
How is Adicet Bio financially positioned?
What strategic collaborations has Adicet Bio entered into?
What is the focus of Adicet Bio's research and development?
What are ADI-001 and ADI-270?
What makes Adicet Bio's approach unique?
What is the significance of the FDA's fast track designation for ADI-001?
Where can I find more information about Adicet Bio?
